Company

Signify Bio

Signify Bio develops personalized nucleic acid-enabled protein therapeutics for genetic and acquired diseases.

About

Signify Bio develops personalized medicines using nucleic acid-enabled protein therapeutics to address genetic and acquired diseases. Founded in 2024 in Dallas, US, the company was established by Lukas Farbiak and RA Session, who serves as CEO. It raised USD 15.00 mn in June 2025 from Actium Group, Bill & Melinda Gates Foundation Trust, Danaher Corporate Development/Ventures, Eli Lilly and Company, and BrightEdge Ventures to advance in situ protein therapeutics and expand operations.

1Funding rounds

2Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in